Biotech

All Articles

AstraZeneca posts information on internal competitors to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared an early take a look at the performance of its own in-house antibod...

iTeos- GSK's TIGIT star shows purposeful renovation

.After declaring a phase 3 launch based on good midstage end results, iTeos as well as GSK are final...

More collaborative FDA may accelerate uncommon ailment R&ampD: record

.The FDA ought to be actually extra open and joint to release a surge in commendations of uncommon a...

Zenas, MBX, Bicara head to Nasdaq in hot time for biotech IPOs

.It is actually an uncommonly active Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara R...

Atea's COVID antiviral stops working to stop hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has neglected another COVID-19 trial, however the biotech still sto...

Neurocrine's bid to conserve schizophrenia possibility falls short

.Neurocrine Biosciences' schizophrenia program pivot has actually failed. The biotech was actually i...

Sanofi pays for $110M upfront for late-stage radioligand therapy

.Sanofi has actually made a late entry to the radioligand gathering, paying 100 thousand euros ($ 11...

F 2G rears $100M for second try to acquire brand-new antifungal to market

.After F2G's 1st attempt to get a new course of antifungal to market was hindered due to the FDA, th...

Moderna targets $1.1 B in R&ampD costs slices, drops 5 systems surrounded by productivity pressures

.Moderna has pledged to reduce R&ampD investing by $1.1 billion through 2027. The decision to retrac...

Sanofi's $80M bank on Key dystrophy drug finishes in stage 3 crash

.Merely four months after Sanofi wager $80 thousand in beforehand money on Pivot Therapies' losmapim...